Mistletoe extract plus pembrolizumab for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests adding a mistletoe extract (Viscum album) to standard immunotherapy (pembrolizumab) for people with triple-negative breast cancer who have had surgery and radiation. The goal is to see if the combination works better than immunotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with triple-negative breast cancer (a type that lacks certain receptors).
- Your daily activity level is normal or only slightly limited (ECOG 0 or 1).
- You have completed surgery and radiation for cancer that hasn't spread, and you are either starting or have started a type of immunotherapy called a checkpoint inhibitor within the last 3 cycles.
- Your blood counts and organ function are within acceptable ranges (like having enough white and red blood cells, and healthy liver and kidneys).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a PD-L1 antibody (a type of immunotherapy) with a low-dose, continuous chemotherapy regimen called VEX for advanced triple-negative breast cancer that has spread to other parts of the body. It may be an option if you have had only one prior chemotherapy for metastatic disease and have already been treated with certain common chemo drugs.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests a new combination of drugs for triple negative breast cancer that has worsened after prior immunotherapy. The goal is to see if these treatments can shrink tumors and help patients who have not responded to earlier immunotherapies.
This trial tests a new combination treatment for metastatic triple-negative breast cancer, using radiation to stimulate the immune system, an immunotherapy drug (pembrolizumab), and a medication that targets immune-suppressing cells. The goal is to boost the body's response to immunotherapy, especially in people who have already received immunotherapy but saw limited benefit.
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
This trial tests a combination of an oral vitamin A-based drug (all-trans retinoic acid) and an immunotherapy (toripalimab) for people with advanced triple-negative breast cancer that hasn't responded to at least two prior treatments. The goal is to see if this combination can shrink or control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.